suPAR Publications and links

Please always find our latest list of suPAR Publications and links to PubMed here:
suPAR Pub Med Publications and Links 2009-2017

The same PubMed list grouped by Organ and Disease here:
suPAR Pub Med Publications and Links - Organ and Disease grouped


Find the full list of suPAR abstracts in PubMed here:
https://www.ncbi.nlm.nih.gov/pubmed/?term=supar

 

suPAR Monograph

On the basis of more than 500 published articles on suPAR in PubMed, a suPAR Monograph has been written.
Here you can find a short summary of the research done on suPAR within 12 groups of disease areas and see how the suPAR level is affected within each kind of disease.
The summary of each disease area is found under Applications here.

key-publications.jpgPlease find the suPAR Monograph here:

suPAR Monograph (English)
suPAR Monografi (Danish)
suPAR Monografia (Spanish)

 

 

 

Key suPAR publications

 March 16, 2018

“Effect of simvastatin and ezetimibe on suPAR levels and outcomes”
published in Atherosclerosis.

suPAR is an inflammatory marker associated with cardiovascular disease. Statins lower both LDL-cholesterol and C-reactive protein (CRP) resulting in improved outcomes. However, whether lipid-lowering therapy also lowers suPAR levels is unknown. The study included 1838 patients with mild-moderate, asymptomatic aortic stenosis, to evaluate relationships between change in suPAR with all-cause mortality and the composite endpoint of major cardiovascular events (MCE) composed of ischemic cardiovascular events (ICE) and aortic valve related events (AVE).

The study concluded that Simvastatin and Ezetimibe treatment impeded the progression of the time-related increase in plasma suPAR levels. The change in suPAR was associated with all-cause mortality, MCE, and AVE.

Find the publication by Hodges GW et al here: https://www.sciencedirect.com/science/article/pii/S0021915018301552

 

February 1, 2018

“suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients” published in Scand J Trauma Resusc Emerg Med.

suPAR is known to be a strong predictor of readmission and mortality in the acute care setting. In this study, it was investigated if suPAR also predicts acute surgery, which is associated with higher mortality than elective surgery, and if it predicts post-operative mortality. The study included 17,312 acute medical patients. The risk of acute surgery during follow-up as well as the 90-day post-operative mortality risk was modeled by Cox regression analyses adjusted for sex, age, C-reactive protein, and Charlson Comorbidity Index (Charlson Score).

The study concluded that elevated levels of suPAR in acutely admitted medical patients were independently associated with increased risk of future acute surgery as well as with 90-day post-operative mortality.

Find the publication by Meyer J et al here: https://sjtrem.biomedcentral.com/articles/10.1186/s13049-018-0478-1

 

October 17, 2017

Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection” published in J Infect Dis.

The study investigated the potential association between suPAR and incident comorbidity and all-cause mortality in a well-treated HIV-infected population.

The study showed that a high suPAR level at baseline was associated with increased risk for cardiovascular disease, chronic kidney disease, chronic lung disease, liver disease, and cancer, and all-cause mortality during follow-up.

Find the publication by Kirkegaard-Klitbo DM et al here: https://academic.oup.com/jid/article/216/7/819/3916663

 

August 23, 2017

“A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease” published in Nature Medicine.

suPAR independently predicts chronic kidney disease incidence and progression.

In this paper, a causal relationship for developing kidney disease between suPAR, APOL1 and αvβ3 integrin is found to cause proteinuria in a suPAR-dependent manner.

Find the publication by Hayek SS et al here: https://www.nature.com/articles/nm.4362

 

September 2, 2016

"suPAR in acute care: A strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study" was published online in EMJ, Emergency Medical Journal in September 2016.

The study included 4343 consecutively admitted patients from the AMU at a large Danish university hospital (Hvidovre).

The conclusion is again, that in an unselected population of acute medical patients;
"A high suPAR level upon admission to the AMU is a marker of severe disease and increased risk of readmission and mortality after adjusting for all other risk factors .... and suPAR adds information to established prognostic indicators".

Patients with low suPAR levels have low risk of readmission and mortality, while patients with high suPAR levels have a high risk of adverse events.

Please find the publication here Line J.H.Rasmussen et al from EMJ

 

November 10, 2015

A study in the New England Journal of Medicine published on November 5 shows that suPAR reliably can predict the development of Chronic Kidney Disease up to five years before symptoms of this disease emerge - a disease that affects an estimated 600 million people.

Currently, physicians rely on two markers to monitor existing kidney disease, but they are not sensitive enough to predict a persons risk of developing the disease or to catch it in its early stages.

The New England Journal of Medicine study found that a high suPAR level was an excellent predictor of future kidney disease.
"We can now stratify people according to their risk of developing kidney disease using suPAR levels" said Dr. Salim Hayek, first author of the study.

The study is even a significant breakthrough in preventive medicine. Also diabetes patients, of which about one-third develop Diabetic Kidney Disease, can now be helped.
"This will help risk-stratify patients with diabetes on their risk of future kidney disease" explains Jochen Reiser, senior author of the NEJM study.

Results are based upon research using the suPARnostic® products from ViroGates.

The New England Journal of Medicine article and abstract
http://www.nejm.org/doi/full/10.1056/NEJMoa1506362

An editorial explaining and commenting on the data
http://www.nejm.org/doi/full/10.1056/NEJMe1512997?rss=searchAndBrowse

ScienceDaily comment on the data set
http://www.sciencedaily.com/releases/2015/11/151105151925.htm